All Stories

  1. Kidney replacement therapy as a key performance indicator for population health. A call to action by REDYT, ALCER, EKPF, S.E.N. and RICORS2040-renal
  2. Clinical characteristics and management of patients with secondary hyperparathyroidism undergoing hemodialysis: a feasibility analysis of electronic health records using Natural Language Processing
  3. Bone Marrow–Derived RIPK3 Mediates Kidney Inflammation in Acute Kidney Injury
  4. Curcumin reduces acute kidney injury and ferroptosis
  5. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases
  6. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts
  7. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression
  8. Correction: Mas, S., et al. Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment. Water 2018, 10, 486
  9. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)
  10. Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment
  11. Fabry disease revisited: Management and treatment recommendations for adult patients
  12. Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields
  13. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
  14. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease
  15. Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
  16. Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation
  17. Enzyme Replacement Therapy for Fabry Disease
  18. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms
  19. Atrial fibrillation in chronic kidney disease
  20. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling
  21. Hypertension in Chronic Kidney Disease Part 1
  22. Hypertension in Chronic Kidney Disease Part 2
  23. Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury
  24. Histone lysine crotonylation during acute kidney injury in mice
  25. Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging
  26. Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials
  27. Clinical management of the uraemic syndrome in chronic kidney disease
  28. Corrigendum to “IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes” [Biochim. Biophys. Acta 1853 (12) (2015) 3224–3234]
  29. NFκBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells
  30. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events
  31. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients
  32. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial
  33. Cómo debemos analizar y describir la mortalidad de nuestros pacientes: experiencia del Grupo Centro Diálisis Peritoneal
  34. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury
  35. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
  36. Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis?
  37. Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants
  38. IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes
  39. The fate of triaged and rejected manuscripts
  40. Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances
  41. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
  42. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition
  43. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes
  44. The double challenge of resistant hypertension and chronic kidney disease
  45. CD74 in Kidney Disease
  46. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification
  47. Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes
  48. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate
  49. Phosphodiesterase type 5 inhibitors and kidney disease
  50. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  51. Timing of eculizumab therapy for C3 glomerulonephritis
  52. Lyso-Gb3 activates Notch1 in human podocytes
  53. Decreasing incidence of renal replacement therapy over time at the critical 50–59-year age range suggests a role for nephroprotective therapy in ADPKD
  54. Humble kidneys predict mighty heart troubles
  55. Translational value of animal models of kidney failure
  56. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function
  57. 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs
  58. Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research
  59. Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology
  60. Designing drugs that combat kidney damage
  61. TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-κB pathway and ERK activation
  62. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
  63. Biocompatibility Reduces Inflammation-Induced Apoptosis in Mesothelial Cells Exposed to Peritoneal Dialysis Fluid
  64. Angiotensin II, via angiotensin receptor type 1/nuclear factor-κB activation, causes a synergistic effect on interleukin-1-β-induced inflammatory responses in cultured mesangial cells
  65. Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort
  66. Albumin-induced apoptosis of tubular cells is modulated by BASP1
  67. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies
  68. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
  69. Healthcare-associated infections: new challenges looking for answers
  70. Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology
  71. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides
  72. Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice
  73. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  74. Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells
  75. TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2
  76. The C-Terminal Module IV of Connective Tissue Growth Factor, Through EGFR/Nox1 Signaling, Activates the NF-κB Pathway and Proinflammatory Factors in Vascular Smooth Muscle Cells
  77. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series
  78. Bicarbonate therapy, phosphate binders, and risk for vascular calcification
  79. Erratum
  80. Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study
  81. Cortisol levels are associated with mortality risk in hemodialysis patients
  82. Klotho Prevents NFκB Translocation and Protects Endothelial Cell From Senescence Induced by Uremia
  83. Urine 2DE proteome analysis in healthy condition and kidney disease
  84. Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis
  85. IL-17A is a novel player in dialysis-induced peritoneal damage
  86. Deferasirox nephrotoxicity—the knowns and unknowns
  87. Application of the New Cholesterol Guidelines
  88. Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation
  89. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians
  90. CXCL16 in kidney and cardiovascular injury
  91. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis
  92. Next-Generation Phosphate Binders: Focus on Iron-Based Binders
  93. Therapeutic approaches to diabetic nephropathy—beyond the RAS
  94. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
  95. The Authors Reply:
  96. Osteoprotegerin and kidney disease
  97. TWEAK Promotes Peritoneal Inflammation
  98. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy
  99. Molecular mediators of favism-induced acute kidney injury
  100. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells
  101. TWEAK and the progression of renal disease: clinical translation
  102. Role of chemokines in proteinuric kidney disorders
  103. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis
  104. Gremlin Activates the Smad Pathway Linked to Epithelial Mesenchymal Transdifferentiation in Cultured Tubular Epithelial Cells
  105. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease
  106. Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis
  107. Individualization of Dialysate Calcium Concentration According to Baseline Pre-Dialysis Serum Calcium
  108. Mitochondria-targeted therapies for acute kidney injury
  109. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease
  110. Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice
  111. 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes
  112. Fn14 in podocytes and proteinuric kidney disease
  113. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation
  114. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells
  115. Subclinical versus overt obesity in dialysis patients: more than meets the eye
  116. p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells
  117. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast
  118. The demise of calcium-based phosphate binders
  119. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry
  120. Unilateral ureteral obstruction: beyond obstruction
  121. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?
  122. A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort
  123. Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis
  124. HCV Infection and Miravirsen
  125. Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine
  126. Connective tissue growth factor is a new ligand of epidermal growth factor receptor
  127. Identification of a Potent Endothelium-Derived Angiogenic Factor
  128. Two independent pathways of regulated necrosis mediate ischemia–reperfusion injury
  129. Macrophages and Recently Identified Forms of Cell Death
  130. Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema
  131. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response
  132. Parathyroid hormone–related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2
  133. Progress in the development of animal models of acute kidney injury and its impact on drug discovery
  134. Klotho to Treat Kidney Fibrosis
  135. Pulmonary Hypertension in CKD
  136. Laser Therapy in Metabolic Syndrome‐Related Kidney Injury
  137. MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple
  138. A Polymeric Nanomedicine Diminishes Inflammatory Events in Renal Tubular Cells
  139. A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI
  140. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+T and NK cells
  141. Fibrosis: a key feature of Fabry disease with potential therapeutic implications
  142. TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease
  143. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
  144. Klotho, phosphate and inflammation/ageing in chronic kidney disease
  145. Vitamin D receptor activation and cardiovascular disease
  146. A role for the membrane proteome in human chronic kidney disease erythrocytes
  147. Klotho modulates the stress response in human senescent endothelial cells
  148. Uromodulin, Inflammasomes, and Pyroptosis
  149. Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells
  150. Notch3 and kidney injury: never two without three
  151. The use of echocardiography in observational clinical trials: the EURECA-m registry
  152. Fabry disease: the many faces of a single disorder
  153. Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?
  154. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
  155. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats
  156. Phosphate: a stealthier killer than previously thought?
  157. Targeting chemokines in proteinuria-induced renal disease
  158. Angiotensin II Contributes to Renal Fibrosis Independently of Notch Pathway Activation
  159. AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
  160. TWEAK (tumor necrosis factor–like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation
  161. High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients
  162. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?
  163. Implementation of proteomic biomarkers: making it work
  164. Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats
  165. Monocyte subpopulations and cardiovascular risk in chronic kidney disease
  166. GSK3, Snail, and Adhesion Molecule Regulation by Cyclosporine A in Renal Tubular Cells
  167. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus
  168. Proteome changes in the myocardium of experimental chronic diabetes and hypertension
  169. The Human Plasma Lipidome
  170. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy
  171. Undetectable serum calcidiol: not everything that glitters is gold
  172. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II
  173. Gremlin Is a Downstream Profibrotic Mediator of Transforming Growth Factor-Beta in Cultured Renal Cells
  174. Risk in Dosing Regimens for 25-OH Vitamin D Supplementation in Chronic Haemodialysis Patients
  175. Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
  176. Haematuria: the forgotten CKD factor?
  177. Oxidative Stress, Macrophage Infiltration and CD163 Expression Are Determinants of Long-Term Renal Outcome in Macrohematuria-Induced Acute Kidney Injury of IgA Nephropathy
  178. Phosphorus and Nutrition in Chronic Kidney Disease
  179. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy
  180. AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences
  181. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis
  182. TWEAK, a multifunctional cytokine in kidney injury
  183. Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?
  184. Delayed Graft Function and Cotrimoxazole
  185. The Inflammatory Cytokines TWEAK and TNF  Reduce Renal Klotho Expression through NF B
  186. Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease
  187. Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?
  188. Glomerulonefritis: concepto y clasificación. Etiopatogenia de las glomerulonefritis
  189. Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems
  190. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases
  191. The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda
  192. The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?
  193. Eficacia de la suplementación oral intradiálisis en pacientes con insuficiencia renal crónica
  194. Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for
  195. Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK
  196. The meaning of urinary creatinine concentration
  197. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients
  198. Soluble TWEAK and PTX3 in Nondialysis CKD Patients: Impact on Endothelial Dysfunction and Cardiovascular Outcomes
  199. Paricalcitol for reduction of albuminuria in diabetes
  200. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications
  201. Animal Models of Cardiovascular Diseases
  202. Calcific uremic arteriolopathy while on cinacalcet
  203. Tenofovir Nephrotoxicity: 2011 Update
  204. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease
  205. Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF-β-Independent Process
  206. Peritonitis Due to Microbacterium sp in a Patient on Cycler Peritoneal Dialysis
  207. Familial C4B deficiency and immune complex glomerulonephritis
  208. New paradigms in cell death in human diabetic nephropathy
  209. Unravelling fibrosis: two newcomers and an old foe
  210. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry
  211. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury
  212. NF- B in Renal Inflammation
  213. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy
  214. 'Reality and desire' in the care of advanced chronic kidney disease
  215. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage
  216. The expanding spectrum of biological actions of vitamin D
  217. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy
  218. UGA hopping: a sport for nephrologists too?
  219. Caspase-12 and Diabetic Nephropathy: From Mice to Men?
  220. Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
  221. Local Non-Esterified Fatty Acids Correlate With Inflammation in Atheroma Plaques of Patients With Type 2 Diabetes
  222. Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy
  223. TWEAK Activates the Non-Canonical NFκB Pathway in Murine Renal Tubular Cells: Modulation of CCL21
  224. BASP1 Promotes Apoptosis in Diabetic Nephropathy
  225. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure
  226. Regulation of Vascular and Renal Cells by Common Mediators in Health and Disease: Role of the Renin—Angiotensin System in the Pathophysiology of Hypertension and Cardiovascular Disease
  227. TNF Superfamily: A Growing Saga of Kidney Injury Modulators
  228. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis
  229. Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria
  230. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
  231. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes
  232. Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease
  233. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice
  234. Estrategias en la profilaxis y el tratamiento de la malnutrición en diálisis peritoneal: un problema infradiagnosticado
  235. A Nanoconjugate Apaf-1 Inhibitor Protects Mesothelial Cells from Cytokine-Induced Injury
  236. 2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece
  237. Inhibition of p38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells
  238. Considering TWEAK as a target for therapy in renal and vascular injury
  239. Patogénesis de la malnutrición en pacientes en diálisis con énfasis en los aspectos más específicos de la diálisis peritoneal
  240. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis
  241. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells
  242. CTGF Promotes Inflammatory Cell Infiltration of the Renal Interstitium by Activating NF- B
  243. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia
  244. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations
  245. Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients
  246. Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity
  247. Essential Role of TGF-β/Smad Pathway on Statin Dependent Vascular Smooth Muscle Cell Regulation
  248. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients
  249. Gliotoxin Inhibits Neointimal Hyperplasia after Vascular Injury in Rats
  250. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation
  251. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis
  252. Mechanisms of Renal Apoptosis in Health and Disease
  253. A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients
  254. ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy
  255. Pharmacological Modulation of Epithelial Mesenchymal Transition Caused by Angiotensin II. Role of ROCK and MAPK Pathways
  256. A Slit in Podocyte Death
  257. 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization
  258. Severe everolimus-associated pneumonitis in a renal transplant recipient
  259. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
  260. Benefits of preserving residual renal function in peritoneal dialysis
  261. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation
  262. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
  263. The Death Ligand TRAIL in Diabetic Nephropathy
  264. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
  265. TWEAKing renal injury
  266. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation
  267. Emphysematous Pyelonephritis in Dialysis Patient After Embolization of Failed Allograft
  268. Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis
  269. Endovascular repair of mycotic aneurysms of the aorta: An alternative to conventional bypass surgery in patients with acute sepsis
  270. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis
  271. Cytokine cooperation in renal tubular cell injury: The role of TWEAK
  272. 3,4-DGE is Important for Side Effects in Peritoneal Dialysis What About its Role in Diabetes
  273. Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience
  274. Peritoneal defence--lessons learned which apply to diabetes complications
  275. Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques: Modulation by Atorvastatin
  276. Lethal activity of FADD death domain in renal tubular epithelial cells
  277. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis
  278. Angiotensin II and Reactive Oxygen Species
  279. Long-Term Blood Pressure Control Prevents Oxidative Renal Injury
  280. 3,4-Dideoxyglucosone-3-ene Induces Apoptosis in Renal Tubular Epithelial Cells
  281. Soporte nutricional en la insuficiencia renal crónica
  282. Role of Bcl-xL in paracetamol-induced tubular epithelial cell death
  283. Modulation of survival in osteoblasts from postmenopausal women
  284. Tight blood pressure control decreases apoptosis during renal damage
  285. Paracetamol-Induced Renal Tubular Injury: A Role for ER Stress
  286. Intracellular Mechanisms of Cyclosporin A-Induced Tubular Cell Apoptosis
  287. Targeting apoptosis in acute tubular injury
  288. Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells
  289. Regulation of apoptosis by lethal cytokines in human mesothelial cells
  290. Staining for cell death
  291. Role of Endogenous Vascular Endothelial Growth Factor in Tubular Cell Protection Against Acute Cyclosporine Toxicity1
  292. Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis
  293. Renal cell loss through cell suicide
  294. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure
  295. The Fas ligand/Fas system in renal injury
  296. Role of cytokines in the response to erythropoietin in hemodialysis patients
  297. Hepatitis B Virus Infection
  298. Circulating Endothelial Cells in Sickle Cell Anemia
  299. Epithelial differentiation of metanephric mesenchymal cells after stimulation with hepatocyte growth factor or embryonic spinal cord.
  300. Cefazolin-Induced Neurotoxicity
  301. Effect of Recombinant Human Growth Hormone in a Postpediatric Hemodialysis Patient with Delayed Growth
  302. Presence of circulating antibodies against brush border antigens (FxlA) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy
  303. Salmonella enteritidis empyema complicating lupus pleuritis.
  304. Involvement of Lipid Mediators in the Pathogenesis of Experimental Nephrosis in Rats: Its Pharmacological Modulation
  305. Role of platelet-activating factor in adriamycin-induced nephropathy in rats
  306. Apoptosis in the Kidney
  307. Nephrotoxicity